WHO Drug Access: Bridging the 2026 Funding Gap

The World Health Organization (WHO) champions global therapeutics trials, but getting a life-saving drug from one of those trials to a patient who needs it is where the whole system often breaks down. We’ve made huge strides in medical science, and collaboration is better than ever, yet the journey from lab bench to a rural clinic remains blocked by stubborn problems with how we fund and distribute medicine. The central, unsolved problem is bridging the gap between a brilliant medical innovation and universal access.

The Chasm of Pharmaceutical Funding and Research Priorities

The simple truth of drug development is that it’s dictated by money. It can cost billions to develop a single new drug, and that number shapes the entire field. As a result, pharmaceutical companies, which answer to shareholders, pour their R&D budgets into diseases common in high-income countries where they can expect a commercial return. This focus on profit means diseases that hammer low- and middle-income countries (LMICs), where purchasing power is low, get left behind. We see enormous investment in oncology and rare diseases for Western markets, while neglected tropical diseases (NTDs) are perpetually scrambling for funding. Efforts exist to fix this. The WHO’s Access to COVID-19 Tools (ACT) Accelerator was a major attempt to separate R&D costs from market prices and push for fair distribution. But these programs often depend on voluntary donations and political goodwill, which you can’t always count on. A 2025 report from the Center for Global Development (CGD) showed that even with more pledges, the money going into R&D for diseases primarily affecting LMICs is nowhere near what’s needed. The tension is obvious: we’re appealing for altruism within a system built on profit. The problem is baked into the system’s design. The WHO can convene experts and set priorities, but it depends on outside partners to actually fund the work. When that funding doesn’t materialize for a specific disease, the trials stall, get downsized, or never get off the ground.

Working through the Labyrinth of Regulatory Hurdles and Local Infrastructure

Even if you get the funding and prove a drug works, getting it to a patient is a nightmare of red tape and broken supply chains. Every country has its own regulatory agency, its own data requirements, and its own slow-moving review process. This creates massive delays. A drug that gets a stamp of approval from the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA) doesn’t just get waved through in sub-Saharan Africa or Southeast Asia. You’re starting from scratch. For every single country, a manufacturer has to compile a new dossier, translate documents, and sometimes conduct new local studies to satisfy unique national guidelines. The agencies themselves are often overwhelmed. A 2024 analysis by the African Medicines Agency (AMA), which is trying to harmonize these rules across the continent, noted that many national regulators just don’t have the staff or technical ability to review novel therapies quickly. So even when a drug is technically available, it can be years before it reaches the people who need it. Then there’s the physical reality on the ground. A new vaccine or monoclonal antibody is useless if it spoils in transit because the cold chain fails, or if there’s no trained healthcare worker who can administer it safely. Many LMICs don’t have the reliable electricity needed for cold storage, the transport networks to reach remote areas, or enough staff. This is where brilliant science fails. Logistical capacity has to be there to support it, and that requires major, long-term investment in things other than the drug itself.

Intellectual Property and Manufacturing Capacity: A Double-Edged Sword

Intellectual property (IP) is a huge and constant sticking point in global health. Patents are designed to give companies a temporary monopoly to recoup their R&D costs, which is supposed to encourage them to invent new things. In practice, this monopoly power keeps prices sky-high and blocks cheaper generic versions from entering the market. Companies sometimes offer voluntary licenses or tiered pricing, but these are often piecemeal solutions that fall way short during a public health emergency, as the intense debates over COVID-19 vaccine patents made painfully clear. The problem is made worse by the fact that most pharmaceutical manufacturing is concentrated in just a few wealthy countries. When a crisis hits and global demand explodes, countries without their own factories are at the mercy of producing nations, stuck at the back of the line. This leaves many LMICs completely vulnerable, a fact they are all too aware of. The real fix is for regions to build their own manufacturing hubs. But this requires huge amounts of capital, a willingness from companies to transfer technology, and a trained local workforce. Efforts like the Partnerships for African Vaccine Manufacturing (PAVM), which has a goal for Africa to produce a large share of its own vaccine needs by 2040, are the right idea, but they need serious political and financial fuel to get there. My take is that the IP system needs an emergency brake for global health crises. Compulsory licensing, where a government can authorize generic production of a patented drug without the patent holder’s consent, is a tool that countries have but are often afraid to use. When people are dying on a massive scale, the argument for prioritizing broad access becomes overwhelming.

Innovative Solutions and Future Pathways for Equitable Access

There’s no single fix here. We need to attack the problem from multiple angles at once: changing the funding model, strengthening global rules, and building local capacity. One set of ideas revolves around changing the money game by separating R&D incentives from sales volume. For instance, with advanced market commitments (AMCs), governments and foundations can guarantee a viable market for a future product, which encourages companies to develop drugs for diseases prevalent in poorer regions by removing the commercial risk. The Gavi COVAX AMC, for all its problems, showed that this kind of mechanism has potential. The WHO itself needs more teeth. It has to be in a position to negotiate better access terms for countries, facilitate real technology transfer, and advocate for global health policies that have some force behind them. We need to move beyond voluntary promises. A binding international treaty on pandemic preparedness, like the one being negotiated now, could create a stronger framework that locks in rules on things like pathogen sharing and ensuring the benefits (like vaccines) are also shared. Those negotiations are stuck on that exact point which shows you how hard it is. Finally, investing in local research, development, and manufacturing in LMICs is a global health security imperative. This means training scientists, building competent and independent regulatory agencies, and creating supply chains that don’t snap during a crisis. Partnerships between universities, local governments, and international organizations can speed this up. Putting vaccine manufacturing centers in Africa, for example, supported by tech transfer from established pharma companies, is a tangible step toward self-sufficiency. These are long-term projects, but they’re the only way to build a more resilient system.

Conclusion

To get the therapies developed in WHO trials to the people who need them, we have to fundamentally re-evaluate how we fund research, regulate drugs, and distribute medicines across the world. The path forward requires a commitment to new financing models that prioritize need over profit, stronger international cooperation with real enforcement, and a serious, sustained investment in building up local capabilities. Only then can we ensure that a medical breakthrough for one is a breakthrough for all.